Adverse events associated with mTOR inhibitors (Q38068519)

28 August 2017

1 reference

title

Adverse events associated with mTOR inhibitors (English)

1 reference

28 August 2017

Nicolas Pallet

1

1 reference

PubMed ID

23252795

28 August 2017

Christophe Legendre

series ordinal

2

1 reference

PubMed ID

23252795

28 August 2017

language of work or name

English

0 references

publication date

20 December 2012

1 reference

Expert Opinion on Drug Safety

28 August 2017

1 reference

28 August 2017

12

1 reference

28 August 2017

177-186

1 reference

28 August 2017

2

1 reference

Human brain tumor xenografts in nude mice as a chemotherapy model.

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Structure of the human mTOR complex I and its implications for rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Control of p70 s6 kinase by kinase activity of FRAP in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Temsirolimus, an inhibitor of mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Rapamycin eluting stent: the onset of a new era in interventional cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

A drug safety evaluation of everolimus in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Temsirolimus: a safety and efficacy review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

mTOR inhibitor-associated proteinuria in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Proteinuria following a switch from calcineurin inhibitors to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus may promote thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Thrombotic microangiopathy after renal transplantation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

mTOR inhibitor-associated dermatologic and mucosal problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus-induced leukocytoclastic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Gastrointestinal leukocytoclastic vasculitis: an adverse effect of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Mammalian target of rapamycin and diabetes: what does the current evidence tell us?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Common toxicities of mammalian target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Sirolimus may reduce fertility in male renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

The multifunctional role of mTOR in innate immunity: implications for transplant immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2013.752814

10.1517/14740338.2013.752814

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23252795